de Melo Gagliato et al., 2014 - Google Patents
Targeting multiple pathways in breast cancerde Melo Gagliato et al., 2014
- Document ID
- 11082979937987697147
- Author
- de Melo Gagliato D
- Gonzalez-Angulo A
- Publication year
- Publication venue
- Breast Cancer Management
External Links
Snippet
Breast cancer (BC) is a highly prevalent disease. Worldwide, it is the most common cancer diagnosed and the leading cause of cancer death in women, making this disease a very important focus of interest and research. There is great heterogeneity in clinical outcomes …
- 206010006187 Breast cancer 0 title abstract description 210
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Luque-Cabal et al. | Mechanisms behind the resistance to trastuzumab in HER2-amplified breast cancer and strategies to overcome it | |
Pietrantonio et al. | Biomarkers of primary resistance to trastuzumab in HER2-positive metastatic gastric cancer patients: the AMNESIA case-control study | |
Choudhury et al. | Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations | |
Sabine et al. | Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study | |
Tobin et al. | The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer | |
Osborne et al. | Mechanisms of endocrine resistance in breast cancer | |
Majewski et al. | PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2–targeted therapies in breast cancer | |
Moroni et al. | Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study | |
Vaz-Luis et al. | Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? | |
Milanezi et al. | EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy | |
Røsland et al. | Novel points of attack for targeted cancer therapy | |
Menyhart et al. | A comprehensive outline of trastuzumab resistance biomarkers in HER2 overexpressing breast cancer | |
Nasrazadani et al. | Precision medicine in hormone receptor-positive breast cancer | |
Montemurro et al. | Biomarkers of drugs targeting HER‐family signalling in cancer | |
DeVita Jr et al. | Cancer: Principles & practice of oncology: Annual advances in oncology | |
Tessari et al. | Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients | |
Pernas et al. | Targeting HER2 heterogeneity in early-stage breast cancer | |
Patel et al. | Personalized treatment for advanced colorectal cancer: KRAS and beyond | |
Triulzi et al. | Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge | |
JP2016535079A (en) | Nucleic acid biomarkers and uses thereof | |
Rickman et al. | Analysis of ErbB receptors in pulmonary carcinoid tumors | |
Zhou et al. | Prognostic and therapeutic molecular markers in the clinical management of esophageal cancer | |
Eng | The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development | |
Clarke et al. | Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors | |
Aftimos et al. | Molecular biology of breast cancer |